View Risk


Article data
Hu (2020)
Risk Factors Associated with Clinical Outcomes in 323 COVID-19
https://doi.org/10.1101/2020.03.25.20037721
https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v2

Results
Treatment
Treatment for COVID-19 (Treated with hypnotics vs. Not received)
COVID-19 (severe/fatal)
Odds ratio: 0.080 (0.030-0.270) Adjusted model

Study characteristics

China

Retrospective cohort study

Medical records

323

Hospitalized patients with COVID-19 in Wuhan.

Of the 323 patients with COVID-19, 186 (57.6%) were rRT-PCR positive and 137 (42.4%) patients were rRT-PCR negative but had typical chest CT image, respiratory symptoms and compatible blood test results at the time of admission. At the end of the study, 252 patients had recovered and were discharged, 35 patients had died (overall case fatality rate, 10.8%), and 36 patients were still hospitalized

Median

28 Day


Results

COVID-19 (severe/fatal)

63

Disease improvement or favorable clinical outcome included full recovery and discharge, progression from critical/severe to non-severe disease status, PCR positive to negative, and/or maintenance of non-severe status. Disease progression or unfavorable clinical outcome included death, progression from non-severe to severe/critical disease status or severe to critical status, and/or maintenance of severe or critical status.

Treatment

Treatment for COVID-19

Survival analysis also confirmed that patients receiving hypnotics had significantly better survival.

Not received

Treated with hypnotics

Odds ratio

0.080 (0.030-0.270)

Yes

No

Yes

Age (patients over 65 years) , smoking , critical disease designation , diabetes, abnormally higher hypersensitive troponin I (>0.04 pg/mL) , leukocyte count (>10x109/L ) and neutrophil count (>75 x109/L)


Other information

At the end of the study, 252 patients had recovered and were discharged, 35 patients had died (overall case fatality rate, 10.8%), and 36 patients were still hospitalized.

Good

Yes

Go Back